Aurobindo Pharma Limited has informed the Exchange about completion of US FDA Inspection at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of the Company
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has informed the stock exchanges that the US FDA has completed its inspection at Unit-IV of APL Healthcare Limited, which is a wholly owned subsidiary of the company. The announcement does not specify the outcome of the inspection, such as whether any observations (Form 483) were issued or whether the inspection was classified as Official Action Indicated (OAI). APL Healthcare is a key manufacturing arm of Aurobindo, and Unit-IV forms part of its production base serving US and other regulated markets. Investors will need to await further details or the next FDA database update to understand the inspection outcome.
Routine disclosure on its own, but FDA inspection outcomes can affect future US approvals and revenue from this unit. Watch for any follow-up filing if the FDA issues observations or a warning letter, which could be negative for the stock.